Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Eukaryotic translation initiation factor 2a
kinase 3 (EIF2AK3; PERK); eukaryotic translation initiation factor 2A
(EIF2A)

Mouse studies suggest inhibiting PERK and EIF2A signaling could help treat radiotherapy-resistant cancers. In mouse xenograft models for human colorectal cancer and glioma, greater PERK and EIF2A signaling was associated with increased tolerance to hypoxia and tumor resistance to radiotherapy compared with normal PERK and EIF2A signaling. In a mouse xenograft model for colorectal cancer with increased PERK and EIF2A signaling, inhibition of EIF2A signaling decreased both hypoxia tolerance and radiotherapy resistance compared with no inhibition. Next steps include developing PERK inhibitors and testing them in preclinical models.

SciBX 6(10); doi:10.1038/scibx.2013.235
Published online March 14, 2013

Unpatented; licensing status not applicable

Rouschop, K.M. et al. Proc. Natl. Acad. Sci. USA; published online March 7, 2013;
doi:10.1073/pnas.1210633110
Contact: Bradly G. Wouters, University of Toronto, Toronto, Ontario, Canada
e-mail:
bwouters@uhnresearch.ca
Contact: Kasper M. Rouschop, Maastricht University Medical Center, Maastricht, the Netherlands
e-mail:
kasper.rouschop@maastrichtuniversity.nl